The Journal of Pediatrics
Volume 156, Issue 4 , Pages 532-536 , April 2010

Maternal Preeclampsia Predicts the Development of Bronchopulmonary Dysplasia

  • Anne R. Hansen, MD, MPH

      Affiliations

    • Division of Newborn Medicine, Children's Hospital, Boston, MA
    • Corresponding Author InformationReprint requests: Anne Hansen, MD, MPH, Children's Hospital, Division of Newborn Medicine, Hunnewell 4, 300 Longwood Ave, Boston MA, 02115.
    • ,
  • Carmen M. Barnés, PhD

      Affiliations

    • Vascular Biology Program, Children's Hospital, Boston, MA
    • ,
  • Judah Folkman, MD

      Affiliations

    • Vascular Biology Program, Children's Hospital, Boston, MA
    • Deceased
    • ,
  • Thomas F. McElrath, MD, PhD

      Affiliations

    • Department of Obstetrics and Gynecology, Maternal-Fetal Medicine, Brigham and Women's Hospital, Boston, MA

Received 15 May 2009 ,Revised 16 September 2009 ,Accepted 15 October 2009.

References 

  1. Mutter WP, Karumanchi SA. Molecular mechanisms of preeclampsia. Microvasc Res. 2008;75:1–8
  2. Koga K, Osuga Y, Yoshino O, Hirota Y, Ruimeng X, Hirata T, et al. Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia. J Clin Endocrinol Metab. 2003;88:2348–2351
  3. Levine R, Maynard SE, Qian C, Lim K, England L, Yu K, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004;350:672–683
  4. Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med. 2006;355:992–1005
  5. Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim YM, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med. 2006;12:642–649
  6. Livingston JC, Chin R, Haddad B, McKinney ET, Ahokas R, Sibai BM. Reductions of vascular endothelial growth factor and placental growth factor concentrations in severe preeclampsia. Am J Obstet Gynecol. 2000;183:1554–1557
  7. Polliotti BM, Fry AG, Saller DN, Mooney RA, Cox C, Miller RK. Second-trimester maternal serum placental growth factor and vascular endothelial growth factor for predicting severe, early-onset preeclampsia. Obstet Gynecol. 2003;101:1266–1274
  8. Tsao PN, Wei SC, Su YN, Chou HC, Chen CY, Hsieh WS. Excess soluble fms-like tyrosine kinase 1 and low platelet counts in premature neonates of preeclamptic mothers. Pediatrics. 2005;116:468–472
  9. Lassus P, Ristimaki A, Ylikorkala O, Viinikka L, Andersson S. Endothelial growth factor in human preterm lung. Am J Respir Crit Care Med. 1999;159:1429–1433
  10. Jakkula M, Le Cras TD, Gebb S, Hirth KP, Tuder RM, Voelkel NF, et al. Inhibition of angiogenesis decreases alveolarization in the developing rat lung. Am J Physiol Lung Cell Mol Physiol. 2000;279:L600–L607
  11. Kasahara Y, Tuder RM, Cool CD, Lynch DA, Flores SC, Voelkel NF. Endothelial cell death and decreased expression of vascular endothelial growth factor and vascular endothelial growth factor receptor 2 in emphysema. Am J Respir Crit Care Med. 2001;163:737–744
  12. Kasahara Y, Tuder RM, Taraseviciene-Stewart L, Le Cras TD, Abman S, Hirth PK, et al. Inhibition of VEGF receptors causes lung cell apoptosis and emphysema. J Clin Invest. 2000;106:1311–1319
  13. Janer J, Andersson S, Kajantie E, Lassus P. Endostatin concentration in cord plasma predicts the development of bronchopulmonary dysplasia in very low birth weight infants. Pediatrics. 2009;123:1142–1146
  14. He Y, Smith SK, Day KA, Clark DE, Licence DR, Charnock-Jones DS. Alternative splicing of vascular endothelial growth factor (VEGF)-R1 (FLT-1) pre-mRNA is important for the regulation of VEGF activity. Mol Endocrinol. 1999;13:537–545
  15. Kendall RL, Wang G, Thomas KA. Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem Biophys Res Commun. 1996;226:324–328
  16. American College of Obstetricians and Gyneclogists . Practice bulletin: diagnosis and management of preeclampsia and eclampsia. Obstet Gynecol. January 2002;2002(99):159–167
  17. McElrath TF, Hecht JL, Dammann O, Boggess K, Onderdonk A, Markenson G, et al. Pregnancy disorders that lead to delivery before the 28th week of gestation: an epidemiologic approach to classification. Am J Epidemiol. 2008;168:980–989
  18. Duff P, Resnick R, Edwards RK. Maternal and fetal infections. In:  Creasy RK,  Resnick R,  Iams JD,  Lockwood CJ,  Moore TR editor. Maternal-Fetal Medicine: Principles and Practice. 6th ed. Philadelphia: Saunders; 2009;p 757
  19. Dales LG, Ury HK. An improper use of statistical significance testing in studying covariables. Int J Epidemiol. 1978;7:373–375
  20. Aslan HGA, Cebeci A. Neonatal outcomes in pregnancies after preterm delivery for HELLP syndrome. Gynecol Obstet Invest. 2004;58:96–99
  21. Gortner L, Wauer RR, Stock GJ, Reiter HL, Reiss I, Jorch G, et al. Neonatal outcome in small for gestational age infants: do they really get better?. J Perinat Med. 1999;27:484–489
  22. Osmanagaoglu M, Mehmet A, Erdogan I, Zengin U, Bozkaya H. Comparison between HELLP syndrome, chronic hypertension, and superimposed preeclampsia on chronic hypertension without HELLP syndrome. J Perinat Med. 2004;32:481–485
  23. Paul DA, Kepler J, Leef KH, Siscione A, Palmer C, Stefano JL. Effect of preeclampsia on mortality, intraventricular hemorrhage, and need for mechanical ventilation in very low-birth-weight infants. Am J Perinatol. 1998;15:381–386
  24. Friedman SA, Schiff E, Kao L, Sibai BM. Neonatal outcome after preterm delivery for preeclampsia. Am J Obstet Gynecol. 1996;174:1788–1792
  25. Seiberth V, Linderkamp O. Risk factors in retinopathy of prematurity: a multivariate statistical analysis. Ophthalmologica. 2000;214:131–135
  26. Bashiri A, Zmora E, Sheiner E, Hershkovitz R, Shoham-Vardi I, Mazor M. Maternal hypertensive disorders are an independent risk factor for the development of necrotizing enterocolitis in very low birth weight infants. Fetal Diagn Ther. 2003;18:404–407
  27. Kurkinen-Raty M, Koivisto M, Jouppila P. Preterm delivery for maternal or fetal indications: maternal morbidity, neonatal outcome and late sequelae in infants. BJOG. 2000;107:648–655
  28. Redline RW, Wilson-Costello D, Hack M. Placental and other perinatal risk factors for chronic lung disease in very low birth weight infants. Pediatr Res. 2002;52:713–719
  29. Kalder M, Ulrich S, Hitschold T, Berle P. Fetal development in mild and severe pre-eclampsia: correlation with maternal laboratory parameters and Doppler ultrasound. Z Geburtshilfe Neonatol. 1995;199:13–17
  30. Korhonen P, Tammela O, Koivisto AM, Laippala P, Ikonen S. Frequency and risk factors in bronchopulmonary dysplasia in a cohort of very low birth weight infants. Early Hum Dev. 1999;54:245–258
  31. Gilbert WM, Young AL, Danielson B. Pregnancy outcomes in women with chronic hypertension: a population-based study. J Reprod Med. 2007;52:1046–1051
  32. Judge GG, Griffiths WE, Hill RC, Lutkepohl H, Lee TC. The Theory and Practice of Econometrics. Second Edition. New York: Wiley; 1985;
  33. Abman SH, Mourani PM, Sontag M. Bronchopulmonary dysplasia: a genetic disease. Pediatrics. 2008;122:658–659
  34. Thebaud B, Ladha F, Michelakis ED, Sawicka M, Thurston G, Eaton F, et al. Vascular endothelial growth factor gene therapy increases survival, promotes lung angiogenesis, and prevents alveolar damage in hyperoxia-induced lung injury: evidence that angiogenesis participates in alveolarization. Circulation. 2005;112:2477–2486
  35. Carmeliet P, Moons L, Luttun A, Vincenti V, Compernolle V, De Mol M, et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med. 2001;7:575–583
  36. Tsao PN, Su YN, Li H, Huang PH, Chien CT, Lai YL, et al. Overexpression of placenta growth factor contributes to the pathogenesis of pulmonary emphysema. Am J Respir Crit Care Med. 2004;169:505–511
  37. Tsao P, Wei SC, Su Y. Lee C, Chou H, Hsieh W, Hsieh F. Placenta growth factor elevation in the cord blood of premature neonates predicts poor pulmonary outcome. Pediatrics. 2004;113:1348–1351
  38. Cheng SL, Wang HC, Yu CJ, Yang PC. Increased expression of placental growth factor in COPD. Thorax. 2008;63:500–506
  39. Barrington KJ, Finer NN. Inhaled nitric oxide for preterm infants: a systematic review. Pediatrics. 2007;120:1088–1099
  40. Kinsella JP, Abman SH. Inhaled nitric oxide in the premature newborn. J Pediatr. 2007;151:10–15
  41. Soll RF. Inhaled nitric oxide in the neonate. J Perinatol. 2009;29(Suppl 2):S63–S67
  42. Kramer BW. Antenatal inflammation and lung injury: prenatal origin of neonatal disease. J Perinatol. 2008;28(Suppl 1):S21–S27
  43. Martin RJ, Walsh MC. Inhaled nitric oxide for preterm infants: who benefits?. N Engl J Med. 2005;353:82–84
  44. Kunig A, Balasubramaniam V, Markham N, Morgan D, Montgomery G, Grover T, et al. Recombinant human VEGF treatment enhances alveolarization after hyperoxic lung injury in neonatal rats. Am J Physiol Lung Cell Mol Physiol. 2005;289:L529–L535

 This study was funded through the generosity of the Lee and Laura Munder Fund. The authors declare no conflicts of interest.

PII: S0022-3476(09)01034-8

doi: 10.1016/j.jpeds.2009.10.018

The Journal of Pediatrics
Volume 156, Issue 4 , Pages 532-536 , April 2010

Article Tools